Items 1 ~ 10 of 2144, Page 1 of 214    Go to Headlines
  09/13/2019 Abbott
Abbott''s Revolutionary FreeStyle® Libre System Now Reimbursed in the Two Largest Provinces in Canada
- Provides broader access to FreeStyle Libre system for residents living with diabetes in Ontario and Quebec
  09/12/2019 Abbott
Abbott Declares 383rd Consecutive Quarterly Dividend
- ABBOTT PARK, Ill., Sept. 12, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.
  09/10/2019 Abbott
Abbott Announces New Data That Shows Artificial Intelligence Technology Can Help Doctors Better Determine Which Patients are Having a Heart Attack
- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis / This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
  09/10/2019 MERCK
Pooled Analysis Continues to Show Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1
- Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung Cancer
  09/10/2019 MERCK
Merck Announces First Nine “Safer Childbirth Cities” Committed to Reducing Maternal Deaths and Narrowing Disparities in the US
- Co-Funders Join Merck for Mothers to Support Newly Formed City-Based Coalitions
  09/09/2019 MERCK
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
- Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official Press Program Data for LYNPARZA Included in ESMO Presidential Symposium and Official Press Program: in Metastatic Castration-Resistant Prostate Cancer (PROfound) and in Advanced Ovarian Cancer (PAOLA-1)
  09/06/2019 Abbott
He''s Back and He''s Hydrated: Abbott and NFL Star Odell Beckham Jr. Partner for Pedialyte®
- Beckham will serve as spokesperson and creative director for Pedialyte / Pedialyte provides advanced rehydration, with an optimal balance of electrolytes and glucose
  09/05/2019 Abbott
Abbott Launches World''s First Pivotal Trial to Test New Approach for Repairing Leaky Tricuspid Heart Valves
- TRILUMINATE Pivotal trial is the world's first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation / There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid valves who are at high risk for surgery / Abbott's TriClip tricuspid valve repair system is built on the company's proven MitraClip technology
  09/05/2019 MERCK
Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
  09/04/2019 MERCK
Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities

<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>